Azenosertib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Azenosertib
- DrugBank Accession Number
- DB18028
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 526.645
Monoisotopic: 526.280472367 - Chemical Formula
- C29H34N8O2
- Synonyms
- 3h-pyrazolo(3,4-d)pyrimidin-3-one, 1-((7r)-7-ethyl-6,7-dihydro-7-hydroxy-5h-cyclopenta(b)pyridin-2-yl)-1,2-dihydro-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-2-(2-propen-1-yl)-
- External IDs
- ZN-C3
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9J13XU96Z1
- CAS number
- 2376146-48-2
- InChI Key
- OXTSYWDBUVRXFF-GDLZYMKVSA-N
- InChI
- InChI=1S/C29H34N8O2/c1-4-14-36-27(38)23-19-30-28(31-21-7-9-22(10-8-21)35-17-15-34(3)16-18-35)33-26(23)37(36)24-11-6-20-12-13-29(39,5-2)25(20)32-24/h4,6-11,19,39H,1,5,12-18H2,2-3H3,(H,30,31,33)/t29-/m0/s1
- IUPAC Name
- 1-[(7R)-7-ethyl-7-hydroxy-5H,6H,7H-cyclopenta[b]pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-(prop-2-en-1-yl)-1H,2H,3H-pyrazolo[3,4-d]pyrimidin-3-one
- SMILES
- CC[C@@]1(O)CCC2=CC=C(N=C12)N1N(CC=C)C(=O)C2=CN=C(NC3=CC=C(C=C3)N3CCN(C)CC3)N=C12
References
- General References
- Not Available
- External Links
- ChemSpider
- 114826635
- ChEMBL
- CHEMBL5095036
- PDBe Ligand
- 05J
- PDB Entries
- 7n3u
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Active Not Recruiting Treatment High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer 1 somestatus stop reason just information to hide 2 Active Not Recruiting Treatment Uterine Serous Carcinoma 1 somestatus stop reason just information to hide 2 Not Yet Recruiting Treatment Uterine Carcinoma / Uterine Malignancies / Uterine Serous Carcinoma 1 somestatus stop reason just information to hide 2 Recruiting Treatment Advanced Pancreatic Adenocarcinoma / Pancreatic Cancer / Pancreatic Ductal Adenocarcinoma (PDAC) 1 somestatus stop reason just information to hide 1 Not Yet Recruiting Treatment Metastatic Colorectal Cancer (CRC) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 3.68 Chemaxon pKa (Strongest Acidic) 13.36 Chemaxon pKa (Strongest Basic) 8.72 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 9 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 100.96 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 163.63 m3·mol-1 Chemaxon Polarizability 59.1 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 08, 2023 03:16 / Updated at September 12, 2023 18:32